Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.6K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.4K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pleural Infection in Adults: Integrating Medical and Surgical Management for Optimal Outcomes.

Thoracic surgery clinics·2026
Same author

Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. <i>Cancers</i> 2026, <i>18</i>, 1037.

Cancers·2026
Same author

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Donor-recipient sex differences: Implications for immunologic outcomes but no impact on survival after lung transplantation.

JHLT open·2026
Same author

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Multiplexed single-cell and spatial profiling reveal B cells and tertiary lymphoid structures as prognostic indicators in pleural mesothelioma.

British journal of cancer·2026
Same journal

Pleuropulmonary Infectious Diseases: Impact of the Diseases and the Scarce Literature.

Thoracic surgery clinics·2026
Same journal

TB or Not TB-Septic or Resect? That Is the Question.

Thoracic surgery clinics·2026
Same journal

Surgery for Pulmonary Aspergillosis.

Thoracic surgery clinics·2026
Same journal

Current Treatment for Mediastinitis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Mucormycosis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Hydatid Disease.

Thoracic surgery clinics·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

Update on Neoadjuvant and Adjuvant Trials.

Raphael S Werner1, Nina Steinmann1, Isabelle Opitz2

  • 1Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

Thoracic Surgery Clinics
|November 19, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors combined with chemotherapy improve outcomes for non-small cell lung cancer (NSCLC). Further research is needed for personalized treatment selection and de-escalation strategies.

Keywords:
Clinical trialsImmunotherapyLung cancerNeoadjuvantPerioperativectDNA

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) is a major global cause of cancer mortality.
  • Neoadjuvant and perioperative immunotherapy combined with chemotherapy represent a significant advancement in NSCLC treatment.
  • These combination therapies have shown improved pathologic response and survival outcomes.

Purpose of the Study:

  • To summarize recent advances in neoadjuvant and perioperative immunotherapy for NSCLC.
  • To highlight the impact of these treatments on response rates and survival.
  • To discuss ongoing research directions, including biomarker development and treatment de-escalation.

Main Methods:

  • Review of landmark phase III clinical trials evaluating immunotherapy plus chemotherapy in NSCLC.
  • Analysis of data on complete response rates, event-free survival, and overall survival.
  • Discussion of current research exploring treatment optimization and personalized medicine approaches.

Main Results:

  • Combination therapy significantly increases complete response rates in NSCLC.
  • Event-free and overall survival are prolonged, particularly in patients with programmed death-ligand 1 (PD-L1)-positive tumors.
  • Ongoing studies are investigating adjuvant immunotherapy and circulating tumor DNA (ctDNA) as predictive biomarkers.

Conclusions:

  • Immune checkpoint inhibitors with chemotherapy are transforming the management of locally advanced NSCLC.
  • Further research is essential for refining patient selection and developing predictive biomarkers.
  • Personalized treatment strategies and de-escalation are key future directions for NSCLC care.